PMID: 6172132Nov 1, 1981Paper

Treatment of NZB/NZW F1 hybrid mice with Mycobacterium bovis strain BCG or type II interferon preparations accelerates autoimmune disease

Arthritis and Rheumatism
E G EnglemanT C Merigan

Abstract

NZB/NZW F1 hybrid mice develop a spontaneous autoimmune disease characterized by the appearance of antinuclear antibodies and premature death due to immune complex glomerulonephritis. To investigate the possible effects of cellular immune stimulation on this disorder, groups of female NZB/NZW mice, aged 2, 5, and 7 months, were treated either with the nonspecific immunostimulatory agent Mycobacterium bovis strain BCG or with saline. Mice treated with BCG at ages 5 and 7 months died sooner than age-matched controls, and death was associated with severe glomerulonephritis, suggesting that BCG may have accelerated autoimmunity in these mice. Since BCG is known to stimulate the production of type II (or gamma) interferon, a substance with potent immunoregulatory effects, a second study was carried out to assess the effects of type II interferon on NZB/NZW disease. A greater number of type II interferon-treated mice died by 9 months of age when compared to controls, and the increased death rate was associated with a more rapid development of antinuclear antibodies and histologically confirmed glomerulonephritis. These data, together with a recent report of increases in the level of serum type II interferon in patients with active sy...Continue Reading

References

Sep 1, 1978·Infection and Immunity·H HeremansP de Somer
Jul 5, 1979·The New England Journal of Medicine·J J HooksA L Notkins
Mar 1, 1968·The Journal of Experimental Medicine·P H Lambert, F J Dixon
Dec 1, 1973·Proceedings of the National Academy of Sciences of the United States of America·M J Dauphinee, N Talal
May 1, 1969·The Journal of Experimental Medicine·R V BlandenG B Mackaness

❮ Previous
Next ❯

Citations

Jan 1, 1990·Pharmacology & Therapeutics·H A Young, K J Hardy
Jan 1, 1987·Immunology Letters·A Schattner
Dec 1, 1994·Immunology Letters·D HartwellD Beller
Apr 26, 2002·Toxicology·J DescotesC Ruat
Sep 1, 1987·The Journal of Experimental Medicine·C O JacobH O McDevitt
Sep 1, 1989·The Journal of Experimental Medicine·K J Hardy, T Sawada
Mar 28, 1998·The Journal of Experimental Medicine·D ZengS Strober
Dec 1, 1983·Annals of the Rheumatic Diseases·M DeGréO Clarke-Jenssen
Dec 23, 2008·American Journal of Respiratory Cell and Molecular Biology·Tsutomu ShinoharaYoshimi Shibata
Oct 17, 2003·The Journal of Clinical Investigation·Defu ZengSamuel Strober
Dec 1, 1981·Journal of Steroid Biochemistry·F HomoF Russo-Marie
Jul 1, 1982·Arthritis and Rheumatism·N TalalD Wofsy
Jan 1, 1984·Annals of the New York Academy of Sciences·O T PrebleJ A Sonnabend
Jun 1, 1988·The American Journal of the Medical Sciences·A Schattner
Oct 30, 2014·European Journal of Immunology·Lei ShenEdgar G Engleman
Oct 2, 2001·Scandinavian Journal of Rheumatology·Y A SigidinS Skurkovich
Jan 1, 1988·Autoimmunity·D A Isenberg, Y Shoenfeld
Oct 1, 1983·Infection and Immunity·S PanemJ Vilcek
Jan 1, 1995·Kidney International·R J JohnsonW G Couser

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.